Metabolics Pharma
Health Care
$5.5Mlatest round · Venture round · Sep 2024 · 2 yr ago
10+team · employees, estimated range
2024founded
15stories in the press
Overview
Create a professional science website with Avada. Showcase research, highlight discoveries, and engage your audience with custom, informative designs.
Funding and backers
Total raised
$5.5M
1 round on record
Latest round
$5.5M
Venture round · Sep 2024 · 2 yr ago
Team
11-50
employees, estimated range
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2024 | $5.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Metabolics Pharma, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Richard LarsonExecutive Officer, DirectorSEC Form D
John DessoukiExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Create a dynamic website for your electrical services with Avada & WordPress. Showcase your expertise, services, and attract clients with…
A professionally designed dispensary website using Avada for WordPress. Showcase products, manage orders, share educational content, and…
Talvy is a video-first networking platform that lets professionals showcase who they are, not just what's on their resume. Create your free…
Start your own small business website with ZenBusiness. Create a business website with easy-to-use AI tools!
Optio is a customer data platform for banks. With the help of Optio, companies can better understand and engage with their customers.
Hotbox's AI trains on your business, engages your audience, and nurtures them to close.
Financials
Total raised
$5.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $5.5M | Details |
People
Richard Larson
Executive Officer, Director
John Dessouki
Executive Officer, Director
Jay Brammer
Director
Mark Finn
Director
Mark Kamp
Director
Barry Miller
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
June 27, 2025 - Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
Your Content Goes Here Press Release DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that
Read more
Report
Report
June 25, 2025 - Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
Your Content Goes Here Press Release ENT-03 was safe and well tolerated at all evaluated doses, with positive efficacy trends DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmac
Read more
Report
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
DOYLESTOWN, Pa., June 25, 2025--Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
Read more
Report
Report
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
Read more
Report
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
Read more
Report
June 20, 2025 - PRESENTATION - Randomized Phase 1a Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes
The post June 20, 2025 - PRESENTATION - Randomized Phase 1a Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes appeared first on Metabolics Pharma.
Read more
Report
June 20, 2025 - ABSTRACT - Randomized Phase 1a Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes
Your Content Goes Here Authors Richard S. Larson, G. Alexander Fleming, Michael B. Zemel, Alan C. Moses Abstract Introduction and Objective: Although GLP-1 agonists show efficacy treating obesity and T2D, significant side effects and high discontinuation
Read more
Report
June 20, 2025 - ABSTRACT - ENT-03 Has Additive Weight Loss and Insulin Normalization Effects with Semaglutide in Diet-Induced Obesity (DIO) in Mice
Your Content Goes Here Authors William A. Kinney, Michael B. Zemel, G. Alexander Fleming, Alan C. Moses, Richard S. Larson, Abstract Introduction and Objective: Obesity and T2D remain major health concerns worldwide. We have recently described a centrally
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Philadelphia
United States
HQ
10-50 est. staff